News | Robotic Systems | August 08, 2019 | Jeff Zagoudis, Associate Editor

Corindus Vascular Robotics to Be Acquired by Siemens Healthineers

All-cash transaction valued at approximately $1.1 billion

Corindus Vascular Robotics to Be Acquired by Siemens Healthineers

August 8, 2019 — Corindus Vascular Robotics announced it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion.

Corindus developed the CorPath platform, the first U.S. Food and Drug Administration (FDA)-cleared medical device for robotic-assisted vascular interventions. The use of a robotic system helps protect cardiac catheterization lab personnel from additional radiation exposure. 

Corindus received FDA clearance for the latest generation of the system, CorPath GRX, in October 2016 for use in coronary PCI; the system earned an additional 510(k) clearance in February 2018 for use in peripheral vascular interventions. As of early 2019, Corindus is also seeking premarket clearance for CorPath GRX in neurovascular interventions. The system has also been featured in several high-profile live case transmissions:  

“We are pleased to have reached this agreement with Siemens Healthineers,” said Mark J. Toland, president and chief executive officer of Corindus. “We believe the transaction will deliver immediate, compelling and certain value to all Corindus stockholders, as well as substantial benefits to our customers. The combination of Siemens Healthineers’ advanced, high-quality imaging, digital and artificial intelligence tools with Corindus’ precision robotics platform has the potential to transform the way healthcare is delivered to those suffering from cardiovascular or peripheral disease. The tremendous technology synergies and shared vision between both companies should allow us to achieve a seamless integration between our businesses.”

“Corindus has established a leading position in vascular robotics with a compelling technology platform for robotic-assisted coronary, peripheral and neurovascular procedures,” said Michel Therin, president, advanced therapies at Siemens Healthineers. “The acquisition of Corindus, combined with Siemens’ strong advanced therapies portfolio will help further advance the growth of vascular robotics. The integration of our technologies could lead to reduced variability, improved efficiency, expanded access to care and ultimately improved patient outcomes. We look forward to welcoming the Corindus team to Siemens Healthineers.”

The transaction has been approved by the board of directors of Corindus and is expected to close in the fourth quarter of 2019, subject to approval by Corindus stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and the satisfaction of other customary closing conditions.

In connection with the transaction, Citigroup Global Markets Inc. is acting as exclusive financial advisor to Corindus and Cadwalader, Wickersham & Taft LLP is serving as its legal advisor.

For more information: www.corindus.com, www.siemens-healthineers.com

Related Content

Innovations Driving the Cath Lab Technology of Tomorrow

Corindus and Houston Methodist DeBakey Heart & Vascular Center Launch Robotic Training Site

Corindus Announces First Patient Enrolled in PRECISION GRX Registry


Related Content

News | Cath Lab

May 16, 2023 — Royal Philips, a global leader in health technology, announced late-breaking data from the DCR4Contrast ...

Home May 16, 2023
Home
News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

Home March 01, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
Subscribe Now